The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial

In this randomised phase II trial the addition of pravastatin to ECC did not improve outcome in patients with advanced gastric cancer. Therefore, further testing of this combination in a randomised phase III trial cannot be recommended.